Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Fifth Third Bancorp

Fifth Third Bancorp raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 94.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,150 shares of the company’s stock after acquiring an additional 6,889 shares during the period. Fifth Third Bancorp’s holdings in Moderna were worth $401,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of MRNA. Assenagon Asset Management S.A. boosted its stake in shares of Moderna by 11.0% during the first quarter. Assenagon Asset Management S.A. now owns 16,623 shares of the company’s stock worth $471,000 after buying an additional 1,645 shares during the period. GAMMA Investing LLC grew its holdings in shares of Moderna by 149.8% during the first quarter. GAMMA Investing LLC now owns 7,926 shares of the company’s stock worth $225,000 after buying an additional 4,753 shares during the last quarter. TB Alternative Assets Ltd. purchased a new position in shares of Moderna during the first quarter worth about $18,495,000. LPF Advisors LLC purchased a new position in shares of Moderna during the first quarter worth about $210,000. Finally, Alpha Wealth Funds LLC purchased a new position in shares of Moderna during the first quarter worth about $425,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Trading Down 1.7%

MRNA stock opened at $25.55 on Wednesday. The firm has a 50 day moving average of $26.29 and a 200-day moving average of $32.74. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $138.07. The company has a market cap of $9.88 billion, a price-to-earnings ratio of -2.93 and a beta of 1.86.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The company had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. During the same period last year, the firm earned ($3.07) EPS. The company’s revenue for the quarter was down 35.3% on a year-over-year basis. Sell-side analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Citigroup assumed coverage on Moderna in a report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price target on the stock. UBS Group lowered their price target on Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Barclays lowered their price target on Moderna from $45.00 to $40.00 and set an “equal weight” rating on the stock in a report on Friday, May 2nd. Royal Bank Of Canada lowered their price target on Moderna from $32.00 to $28.00 and set a “sector perform” rating on the stock in a report on Friday, May 2nd. Finally, William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday, June 2nd. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and a consensus price target of $46.61.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.